Survival of Mexican Children with Acute Lymphoblastic Leukaemia under Treatment with the Protocol from the Dana-Farber Cancer Institute 00-01.
Our aim in this paper is to describe the results of treatment of acute lymphoblastic leukaemia (ALL) in Mexican children treated from 2006 to 2010 under the protocol from the Dana-Farber Cancer Institute (DFCI) 00-01. The children were younger than 16 years of age and had a diagnosis of ALL de novo. The patients were classified as standard risk if they were 1-9.9 years old and had a leucocyte count <50 × 10(9)/L, precursor B cell immunophenotype, no mediastinal mass, CSF free of blasts, and a good response to prednisone. The rest of the patients were defined as high risk. Of a total of 302 children, 51.7% were at high risk. The global survival rate was 63.9%, and the event-free survival rate was 52.3% after an average follow-up of 3.9 years. The percentages of patients who died were 7% on induction and 14.2% in complete remission; death was associated mainly with infection (21.5%). The relapse rate was 26.2%. The main factor associated with the occurrence of an event was a leucocyte count >100 × 10(9)/L. The poor outcomes were associated with toxic death during induction, complete remission, and relapse. These factors remain the main obstacles to the success of this treatment in our population.
Departamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo S/N colonia La Raza, 02990 Mexico, DF, Mexico.
Elva
E
Jiménez-Hernández
Departamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo S/N colonia La Raza, 02990 Mexico, DF, Mexico.
Ethel Zulie
EZ
Jaimes-Reyes
Laboratorio de Investigación, Hospital Infantil de México "Federico Gómez", Secretaría de Salud, Calle Doctor Marquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 Mexico, DF, Mexico.
José
J
Arellano-Galindo
Facultad de Medicina, Universidad Nacional Autónoma de México, Avenida Universidad 3000, 04510 Mexico City, DF, Mexico.
Xochiketzalli
X
García-Jiménez
Departamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo S/N colonia La Raza, 02990 Mexico, DF, Mexico.
Héctor Manuel
HM
Tiznado-García
Departamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo S/N colonia La Raza, 02990 Mexico, DF, Mexico.
María Teresa
0000-0002-4582-4594
MT
Dueñas-González
Departamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo S/N colonia La Raza, 02990 Mexico, DF, Mexico.
Octavio
0000-0001-8881-1104
O
Martínez Villegas
Departamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo S/N colonia La Raza, 02990 Mexico, DF, Mexico.
Berenice
B
Sánchez-Jara
Departamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo S/N colonia La Raza, 02990 Mexico, DF, Mexico.
Vilma Carolina
VC
Bekker-Méndez
Departamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo S/N colonia La Raza, 02990 Mexico, DF, Mexico.
María Guadalupe
MG
Ortíz-Torres
Departamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo S/N colonia La Raza, 02990 Mexico, DF, Mexico.
Antonio
A
Ortíz-Fernández
Departamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo S/N colonia La Raza, 02990 Mexico, DF, Mexico.
Teresa
T
Marín-Palomares
Unidad de Investigación en Epidemiología Clínica, UMAE Hospital de Pediatría, Centro Médico Nacional "Siglo XXI", IMSS, Avenida Cuauhtemoc 330, 4to Piso Edificio de la Academia Nacional de Medicina, 06720 Mexico, DF, Mexico.
Juan Manuel
JM
Mejía-Aranguré
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008800:Mexico; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D011241:Prednisone; D008727:Methotrexate